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A patent foramen ovale (PFO) is an intracardiac shunt pathway present in 
approximately one-third of the general, healthy population that allows varying degrees 
of blood flow to pass directly from the right to the left heart, bypassing pulmonary 
circulation and gas exchange at the lungs. Subjects with a PFO (PFO+) exhibit higher 
alveolar to arterial oxygen difference (AaDO2) values at rest than subjects without a 
PFO (PFO–), indicating that PFO+ subjects have a source of right-to-left shunt 
significant enough to decrease gas exchange efficiency at rest (Lovering et al., 2011). 
Additionally, PFO+ subjects have blunted ventilatory acclimatization to hypoxia 
compared to PFO– subjects (Elliott et al., 2015). Therefore, the aim of this research was 
to determine if the presence of a PFO affects an individual’s response to acute 
hypercapnic conditions, as quantified by calculating each individual’s hypercapnic 
ventilatory response (HCVR). It was hypothesized that, when compared to PFO- 
subjects, PFO+ subjects would exhibit a blunted HCVR during exposure to normoxic 
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hypercapnia and hyperoxic hypercapnia when compared to PFO- subjects. Accordingly, 
31 healthy, non-smoking subjects – 16 PFO+ (9 female) and 15 PFO- (8 female) – 
participated in this study. Subjects completed both a normoxic hypercapnia (NH) and 
hyperoxic hypercapnia (HH) breathing trial, in a randomized and balanced order, 
separated by ≥ 40 minutes. End-tidal oxygen and carbon dioxide (PETO2 and PETCO2) 
were controlled utilizing a dynamic end-tidal forcing system (AirForce). During the HH 
trial, PETO2 was clamped at 250 mmHg and PETCO2 was increased in a stepwise 
fashion to target values of +3 mmHg, +6 mmHg and +9 mmHg of each subject’s 
baseline PETCO2. Each stage consisted of a 90 second steady-state data collection 
period after each increase. The procedure for the NH was identical to the HH trial 
except that PETO2 was clamped at the resting baseline value for each subject and 
PETCO2 increased as above. Hypercapnic ventilatory response (HCVR) was calculated 
as slope of the ventilation (VE) versus end-tidal carbon dioxide (PETCO2) regression 
line for each subject (L/min/mmHg CO2). PFO+ subjects demonstrated a blunted 
HCVR in both the NH and HH trials compared to PFO- subjects (p < .05). Overall, 
these results indicate that PFO+ subject have a blunted response to acute hypercapnic 
challenges in both normoxic and hyperoxic conditions suggesting a difference in central 
but not peripheral chemosensitivity to increased CO2. Therefore, PFO+ subjects may be 
more susceptible to developing sleep apnea and subsequent comorbidities as a result of 
differences in central CO2 chemosensitivity. 
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Abbreviations and Terms 
 
AaDO2: alveolar-arterial oxygen gradient; difference between the alveolar and arterial 
concentrations of oxygen 
 
BMR: basal metabolic rate; rate of energy expenditure at rest 
 
Central chemoreceptors: areas of highly sensitive tissue located in the medulla 
(brainstem); primary sensors of PaCO2 
 
CNS: central nervous system 
 
CSF: cerebrospinal fluid 
 
DEF: dynamic end-tidal forcing system; system utilized in this experiment to control 
and estimate arterial blood gases in place of an arterial line 
 
ECF: extracellular fluid 
 
FiCO2: fraction of inspired carbon dioxide 
 
FiO2: fraction of inspired oxygen 
 
HH: hyperoxic hypercapnia 
 
Hypercapnia: condition of increased blood carbon dioxide  
 
HCVR: hypercapnic ventilatory response; ∆𝑉𝑉𝐸𝐸
∆𝑃𝑃𝐸𝐸𝐸𝐸𝐶𝐶𝑂𝑂2
 measures change in ventilation 
compared to change in arterial partial pressure of carbon dioxide to quantify an 
individual’s response to hypercapnic conditions. Calculated as the slope of the VE vs. 
PETCO2 regression line for each subject in each trial in this experiment.  
 
Hyperoxia: condition of increased blood oxygen  
 
Hyperthermia: condition of increased body temperature 
 
Hypoxia: condition of decreased blood oxygen  
 
HVR: hypoxic ventilatory response; ∆𝑉𝑉𝐸𝐸
∆𝑆𝑆𝑆𝑆𝑂𝑂2
 measures change in ventilation compared to 
change in arterial oxygen saturation to quantify an individual’s response to hypoxic 
conditions 
 
Interatrial septum: heart wall separating the right and left atria; location of a patent 
foramen ovale (PFO) 
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IV: intravenous 
 
NH: normoxic hypercapnia 
 
Normoxia: condition of baseline level of oxygen, as determined by each individual’s 
resting steady state 
 
NTS: nucleus tractus solitarius 
 
OSA: obstructive sleep apnea 
 
PACO2: alveolar partial pressure of carbon dioxide 
 
PaCO2: arterial partial pressure of carbon dioxide 
 
PaO2: arterial partial pressure of oxygen 
 
PFO: patent foramen ovale; intracardiac shunt pathway between right and left atria of 
heart  
 
Peripheral chemoreceptors: areas of highly sensitive tissue located in the carotid bodies 
and aortic arch; primary sensors of PaO2 
 
PETCO2: end-tidal (expired) partial pressure of carbon dioxide 
 
PETO2: end-tidal (expired) partial pressure of oxygen  
 
PFT: pulmonary function testing; technique utilized to assess lung function in all 
subjects and ensure that no subjects exhibit signs of lung disease 
 
RR: respiratory rate (breaths/min) 
 
RTLS: right-to-left shunt 
 
Saline-contrast echocardiography: technique utilized for PFO screening. Microbubbles 
are injected into a peripheral vein and viewed in the heart using ultrasound imaging 
 
SaO2: arterial oxygen saturation 
 
SpO2: predicted arterial saturation of oxygen 
 
Valsalva maneuver: technique utilized to increase right atrial pressure above left atrial 
pressure, causing shunting through a PFO if present 
 
VE: ventilation (L/min) 
   x 
 
Ventilatory acclimatization: increase in ventilation (VE) that occurs in response to 
extended exposure to high altitude 
 
VT: tidal volume (L) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
  
Introduction: 
For the past two years, I have had the privilege of working as an undergraduate 
research assistant in Dr. Andrew Lovering’s Cardiopulmonary and Respiratory 
Physiology Lab within the Human Physiology Department at the University of Oregon. 
One of the chief research focuses of this lab is to investigate the physiological 
implications of a patent foramen ovale (PFO), an intracardiac shunt pathway present in 
~25-40% of the general, healthy population (Woods et al., 2010; Marriott et al., 2013; 
Elliott et al., 2013). Individuals with a PFO (PFO+) have varying degrees of blood flow 
traveling directly from the right to left atrium, and therefore bypassing gas exchange in 
the lungs. There are several established effects of PFO, including increased gas 
exchange inefficiency at rest due to shunting through the interatrial opening (Lovering 
et al., 2011). PFO+ subjects have also been demonstrated to have ~0.4° C higher core 
temperature when compared to those without a PFO (PFO-) (Davis et al., 2015). In 
addition, research suggests a difference in ventilatory acclimatization between PFO+ 
and PFO- populations (Elliott et al., 2015). Despite its prevalence, relatively limited 
research investigating the potential impacts of a PFO on normal physiology exists.  
Ventilatory responses to hypercapnic and hypoxic ventilatory challenges have 
been studied in a variety of conditions and populations. Responses to hypercapnic 
environments can be quantified and compared by measuring the hypercapnic ventilatory 
response (HVCR). HCVR is calculated by comparing a change in ventilation to a 
change in arterial partial pressure of carbon dioxide (PaCO2), which can be estimated 
using end-tidal CO2 (PETCO2). However, the influence of a PFO on these responses has 
yet to be elucidated. Therefore, the purpose of this study and thesis was to determine if 
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the presence of a PFO affects an individual’s response to hypercapnic ventilatory 
challenges. This purpose was tested by measuring ventilatory responses to two 
hypercapnic conditions in male and female subjects with and without a PFO. It was 
hypothesized that, compared to PFO- subjects, PFO+ subjects would demonstrate a 
blunted HCVR to acute exposure to hyperoxic hypercapnia (HH) and normoxic 
hypercapnia (NH). 
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Background 
 
Cardiopulmonary Physiology 
The cardiopulmonary system functions primarily to transport oxygen (O2) and 
additional nutrients to peripheral tissues while concomitantly removing carbon dioxide 
(CO2) and other metabolic waste products. Oxygen poor, venous blood from the 
systemic circulation enters the right side of the heart before being pumped to the 
pulmonary circulation. Following gas exchange in the lungs, oxygenated blood travels 
to the left heart for distribution throughout the body (Figure 1). These are vital 
functions, as oxygen is necessary for cellular respiration and energy production, while 
carbon dioxide must be removed for pH buffering and maintenance of homeostatic 
conditions (Hall, 2011).  
 
Patent Foramen Ovale 
The foramen ovale is an opening in the interatrial septum of the fetal heart that 
allows blood to flow directly from the right to the left atrium. In utero, a human embryo 
receives oxygenated blood from its mother, as the developing lungs do not yet perform 
gas exchange. Therefore, the foramen ovale allows the majority of blood flow to bypass 
pulmonary circulation during gestation and flow directly into the left heart for 
distribution to the body (Rasanen, 1996).  
While the foramen ovale is patent in all healthy humans during fetal 
development, this opening typically closes shortly after birth. When the lungs become 
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functional at the commencement of ventilation, pulmonary vascular resistance, and 
therefore pulmonary pressure, decrease causing left atrial pressure to exceed right atrial 
pressure. This pressure gradient alteration forces the septum primum, a flap of tissue in 
the left atrium, against the foramen ovale, resulting in functional closure. The tissue flap 
eventually fuses to the interatrial septum, permanently occluding the opening in the 
majority of humans. However, studies utilizing saline contrast echocardiography have 
shown that the hole fails to close completely in ~25-40% of the population (Woods et. 
al., 2010; Marriott et al., 2013; Elliott et al., 2013), and is termed a patent foramen ovale 
(PFO). In otherwise healthy subjects, this intracardiac shunt pathway can allow up to 
5% of cardiac output to flow directly from the right heart to the left heart (Figure 2), 
bypassing pulmonary circulation and therefore gas exchange (Devuyst, 2004).  
 
Functions of the Lungs 
While the lungs fulfill multiple roles in the human body, the primary function of 
the respiratory system is gas exchange at the level of the alveoli. Pulmonary alveoli, the 
saccular units of the lung, fill with air during respiration. Pulmonary capillaries deliver 
oxygen poor, carbon dioxide rich blood to the alveolus, where carbon dioxide diffuses 
out of the blood and into the alveolus for expiration. Oxygen concurrently diffuses from 
the alveolus into the capillary for transport back to the heart and eventual delivery to 
peripheral tissues (Hall, 2011).  
 Gas exchange efficiency can be quantified by determining the difference 
between the alveolar and arterial partial pressures of oxygen, known as the alveolar-
arterial oxygen difference (AaDO2). This value represents the ability of oxygen to 
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diffuse effectively from the alveoli to the blood. The smaller the AaDO2 value and more 
minimal the difference in oxygen partial pressures, the greater the pulmonary gas 
exchange efficiency. However, conditions such as right-to-left shunt or ventilation-
perfusion mismatch lead to increases in AaDO2 values, denoting a greater degree of gas 
exchange inefficiency. Because blood traveling through a PFO bypasses pulmonary 
circulation, Lovering et al. sought to establish the effect of a PFO on pulmonary gas 
exchange efficiency in otherwise healthy humans. This research determined that PFO+ 
subjects exhibit a higher AaDO2 at rest than PFO- subjects, indicating that PFO+ 
subjects have a higher gas exchange inefficiency in resting conditions, as would be 
predicted with an additional source of right-to-left shunt (Lovering et al., 2011).  
 In addition to performing gas exchange, it has been suggested that the lungs 
facilitate some degree of heat dissipation through respiratory cooling. Cabanac and 
White established that when core temperature reaches a threshold of approximately 
38.5°C in hyperthermic conditions, ventilation increases 2-3 fold. While the cause of 
this increase in ventilation observed in concert with increased core temperature is not 
yet fully understood, it is estimated that respiratory cooling as a secondary function of 
the lungs accounts for a 10% of heat loss. Therefore, ventilation may increase with 
increased core temperature in order to augment heat dissipation occurring at the lungs 
(Cabanac and White, 1995). 
 
Chemical Control of Breathing 
Respiratory rate (RR) is principally determined by oxygen, carbon dioxide and 
pH quantities in the blood. Arterial partial pressure of CO2 (PaCO2) is primarily sensed 
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by central chemoreceptors located in the ventrolateral portion of the medulla within the 
central nervous system (CNS). The central medullary chemoreceptors are composed of 
neural tissue that is highly sensitive to changes in the hydrogen ion (H+) concentration, 
and therefore pH, of the brain extracellular fluid (ECF). Though CO2 predominantly 
travels through the bloodstream as bicarbonate (HCO3-), the blood-brain barrier is 
relatively impermeable to bicarbonate as well as hydrogen ions, preventing 
chemoreceptors from sampling the CO2 levels of the blood directly. However, carbon 
dioxide itself easily traverses the blood brain barrier, after which carbonic anhydrase 
catalyzes the conversion of CO2 and water to carbonic acid (H2CO3), which then 
dissociates into bicarbonate and hydrogen ions within the ECF and cerebral spinal fluid 
(CSF).  Central chemoreceptors sense hydrogen ion concentration and therefore 
indirectly monitor PaCO2 through changes in ECF and CSF pH. The respiratory pattern 
generator within the medulla then integrates signals from central chemoreceptors and 
modulates a response based on the firing rate of the chemoreceptors. The signal is 
relayed to the diaphragm and accessory respiratory muscles to stimulate a change in the 
rate of contraction, which causes an increase in ventilation (West et al., 2013).   
 While carbon dioxide is primarily sensed by central chemoreceptors, peripheral 
chemoreceptors located in the carotid and aortic bodies primarily maintain blood 
oxygen homeostasis. Peripheral chemoreceptors sense the arterial partial pressure of 
oxygen (PaO2) and respond to conditions of low oxygen (hypoxia). Carotid bodies are 
composed of glomus cells, which sense oxygen and release transmitters in response to 
hypoxia (Prabhakar et al., 2004). These chemoreceptors signal to the nucleus tractus 
solitarius (NTS), a specialized area of the medulla, which relays information to the 
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respiratory pattern generator, eventually leading to contraction of the muscles necessary 
for inspiration (Smith et al., 2010). When PaO2 decreases, peripheral chemoreceptor 
firing rate increases, resulting in increased ventilation in order to return oxygen to 
normal range levels (West et al., 2013).  
 The central and peripheral chemoreceptors have traditionally been thought to 
operate independently. However, recent research suggests that the responses of these 
chemoreceptors are integrated and interdependent. Studies in canine models suggest a 
hyperadditive effect of chemoreception on ventilation, whereby the response of central 
chemoreceptors to increased PaCO2 is influenced by and dependent upon a concomitant 
response by the peripheral chemoreceptors (Blain et al., 2010). In the interdependent 
model, it is speculated that peripheral chemoreceptor outputs have the potential to affect 
central chemoreceptor outputs via signal transduction through the NTS. This model 
challenges traditional understanding of chemoreceptor influences on ventilation, 
whereby the central chemoreceptors and peripheral chemoreceptors signal to the central 
respiratory pattern generator independently (Smith et al., 2010).  
 While both hypoxic and hypercapnic conditions provide powerful chemical 
drives to breathe, basal metabolic rate (BMR), and therefore rate of production of 
carbon dioxide, drives ventilation at sea level. At low elevation, the partial pressure of 
oxygen is high such that the need to maintain oxygen saturation of the blood only 
minimally drives ventilation, if at all. Carbon dioxide is produced as a byproduct of 
cellular metabolism and must be exhaled for elimination from the body. Therefore, the 
build-up of carbon dioxide from basal, or resting, metabolism determines respiratory 
rate in non-altitude conditions (Nattie et al., 2005).  
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Hypercapnic and Hypoxic Ventilatory Responses 
The hypercapnic ventilatory response (HCVR) measures the change in 
ventilation over the change in arterial partial pressure of carbon dioxide (PaCO2) and 
provides a method to quantify an individual’s response to hypercapnic, or high carbon 
dioxide, conditions. A greater HCVR denotes a larger response and chemosensitivity to 
a given change in arterial CO2. Similarly, the hypoxic ventilatory response (HVR) 
compares change in ventilation to change in arterial oxygen saturation (SaO2) and 
measures the response to hypoxic, or low oxygen, conditions. A larger HVR signifies a 
greater change in ventilation in response to hypoxia, and HVR has been shown to 
increase with ventilatory acclimatization to altitude (West et al., 2013).  
 
Obstructive Sleep Apnea and PFO 
 Obstructive sleep apnea (OSA) is a sleep disorder characterized by partial or 
complete occlusions of the upper airway that result in repetitive hypopneas (reduced 
airflow) or apneas (cessation of airflow) and a periodic breathing pattern during sleep. 
The current prevalence of OSA in the United States is estimated to be 9% among 50 to 
70-year-old women and 17% among 50 to 70-year-old men, with increases in 
prevalence as high as 55% in the past two decades (Peppard et al., 2013). Sleep-
disordered breathing, which leads to sleep fragmentation and nocturnal hypoxemia, can 
increase risk of severe health detriments, including systemic hypertension, coronary 
artery disease, insulin insensitivity, and stroke (Dempsey et al., 2012). Thus, a large 
portion of the United States adult population is at risk of developing serious and life-
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threatening health complications at some point in life secondary to obstructive sleep 
apnea.  
 There is a greater prevalence of PFO among patients with severe obstructive 
sleep apnea (43-72%) than in the general healthy population (Shanoudy et al., 1998; 
Guchlerner et al., 2012; Shaikh et al., 2013). A recent study concluded that the presence 
of a PFO exacerbates the severity of obstructive sleep apnea and that PFO closure in 
patients with severe OSA can decrease apnea-hypopnea index (AHI) values, improve 
oxygen desaturation index (ODI), and decrease both nocturnal and daytime systolic 
blood pressure. Upper airway closure and subsequent breathing effort against the closed 
airway is believed to increase right atrial pressure above left atrial pressure, similar to 
the performance of a Valsalva maneuver, which increases flow across a PFO, worsening 
hypoxemia (Rimoldi et al., 2015). However, the exact physiological correlations 
between OSA and PFO have yet to be fully elucidated. One reason may be that PFO+ 
subjects may be prone to a relatively greater hypoventilation during sleep, which may 
subsequently predispose these subjects to central sleep apnea (Dempsey, 2010).  
 
The Effect of Biological Sex on Ventilatory Responses 
 Sex hormones, namely testosterone, estrogen and progesterone, have significant 
effects on the central neural control of breathing (Behan et al., 2003). Progesterone, a 
steroidal sex hormone that is normally high during the luteal phase of the menstrual 
cycle, is a known ventilatory stimulant (White et al., 1983). Additional research has 
shown that sex hormones influence resting minute ventilation (VE). In a recent 
comprehensive study, MacNutt et al. determined that there is a clear effect of menstrual 
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cycle phase on resting VE. Body surface area (BSA) corrected VE was demonstrated to 
be higher during the mid-luteal (ML) phase of the menstrual cycle, when estrogen and 
progesterone levels are high, compared to the early follicular (EF) and late follicular 
(LF) phases (MacNutt et al., 2012). However, the effects of biological sex and sex 
hormones on ventilatory responses to hypoxia and hypercapnia have been historically 
equivocal. Previous research has demonstrated hypoxic chemosensitivity in males to be 
greater (White et al., 1983), lesser (Aitken et al., 1986), as well as no different (Jensen 
et al., 2004) when compared to females in resting conditions. MacNutt et al. attribute 
the disparities among results to inconsistencies and inaccuracies in assessing menstrual 
cycle phase, as well as variability in methods used to measure hypoxic 
chemosensitivity. After correcting for these potential sources of discrepancy, it was 
ultimately determined that ventilatory responses to hypoxia and hypercapnia are 
unaffected by biological sex or menstrual cycle phase (MacNutt et al., 2012). However, 
previous research into the effects of biological sex and sex hormones on ventilation has 
not taken into account the possible influence of the presence of a PFO on ventilatory 
responses. 
 
The Effect of a Patent Foramen Ovale on Ventilatory Responses 
 While one may expect that PFO+ individuals, who have some amount of cardiac 
output bypassing gas exchange at the lungs, would exhibit augmented ventilatory 
responses to hypoxic and thermoregulatory challenges, recent research by Elliott et al. 
and Davis et al. suggests otherwise.  
   11 
 In 2012 the Cardiopulmonary and Respiratory Physiology Lab traveled to Mt. 
Chacaltaya, Bolivia to study the effect of PFO on ventilatory acclimatization. Twenty-
one healthy, sea level residents (11 PFO+) were utilized for this study. Resting and 
exercise measurements were taken at sea level, following acute transport to 5260m 
(~17,000ft), and after 16 days at elevation. There were no significant differences in 
HVR after one day at altitude between PFO+ and PFO- groups. However, following 16 
days at elevation, PFO- subjects demonstrated a significant increase in breathing when 
compared to day one measures. In addition, PFO- subjects had a significantly larger 
increase in breathing with acclimatization than PFO+ subjects at the day 16 time point. 
Conversely, PFO+ subjects exhibited no significant change in breathing from day 1 to 
day 16 at altitude, suggesting that individuals with a PFO have blunted ventilatory 
acclimatization to high altitude (Elliott et al., 2015). 
 Similarly, unpublished data from a recent study conducted by Davis et al. shows 
that subjects with a PFO demonstrate a blunted ventilatory response to passive heating. 
For this experiment, PFO+ and PFO- subjects were immersed in a 40°C hot tub for 30 
minutes while ventilation, among other factors, was measured. Although PFO+ subjects 
consistently maintain a ~0.4°C higher core temperature than PFO- subjects, PFO- 
subjects in this study showed a significantly greater increased ventilation in response to 
increased core temperature, compared to the PFO+ group.  
 While previous studies have explored the effect of a PFO on hypoxic and 
thermoregulatory challenges, the influence of a PFO on the hypercapnic ventilatory 
response (HCVR) remains unknown. Because PFO+ individuals have some degree of 
blood flow bypassing gas exchange at the lungs and therefore exhibit greater gas 
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exchange inefficiency and higher PaCO2, it could be expected that PFO+ subjects 
would demonstrate a greater increase in ventilation and larger HCVR than PFO- 
subjects. However, Elliott et al. and Davis et al. have recently established that PFO+ 
subjects show a blunted ventilatory response to chronic hypoxia exposure, as well as 
acute exposure to heat. In combination, these results led to the purpose and hypothesis 
for this thesis.  
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Methods 
 
This study was approved by the University of Oregon’s Office for Protection of 
Human Subjects. Each subject was provided documentation outlining the experiment 
and gave written consent prior to participation. Experimental procedures were 
conducted in accordance with the Declaration of Helsinki.  
 
Subjects 
 
A total of 31 subjects (17 female) volunteered, and were included in this study. 
The experiment was explained in detail to all subjects both orally and in writing, and 
each individual provided written consent to participate. All subjects were non-smoking 
individuals with no history of cardiopulmonary disease. Of the 14 male subjects, there 
were 7 PFO+ subjects and 7 PFO- subjects and of the 17 female subjects, 9 were PFO+ 
and 8 were PFO-. There were no significant differences between PFO+ and PFO- 
groups in age, height, weight, or body surface area (Table 1).  
 
PFO Detection: Saline-Contrast Echocardiography 
 
The presence of a PFO was determined using saline-contrast echocardiography 
(Lovering and Goodman, 2012).  The screening was performed with the subject 
breathing room air, seated, and positioned on their left side in an IV chair reclined at a 
45° angle. The subject was instrumented with an intravenous catheter (20-22G) attached 
to a three-way stopcock and extension system in the antecubital fossa. Two syringes, 
one containing 3 ml of sterile saline and the other containing 1 ml of room air, were 
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attached to the stopcock. The contents of the two syringes were combined and agitated 
for 10-15 seconds and the resulting microbubbles were injected into a peripheral vein 
via the IV catheter. Ultrasound imaging (Philips ie33) was utilized to view all four 
chambers of the heart in an apical view (echocardiogram). Microbubbles were injected 
and viewed during normal tidal breathing, as well as immediately following the release 
of a Valsalva maneuver. The Valsalva maneuver is a technique utilized to increase right 
atrial pressure above left atrial pressure and allow right-to-left heart blood flow if a PFO 
is present. The Valsalva maneuver was determined effective if a leftward shift of the 
interatrial septum was observed.  
 Following each saline-contrast injection, the subsequent 20 cardiac cycles were 
recorded to determine the presence of a PFO. Within 3-5 cardiac cycles of injection, a 
cloud of microbubbles appeared within the right heart chambers. The presence of any 
microbubbles in the left heart within the next 20 heartbeats constituted evidence for the 
existence of either a PFO or intrapulmonary shunt. The subject was determined to have 
a PFO (PFO+) if contrast appeared within the left atrium or ventricle in ≤ 3 cardiac 
cycles (Marriott et al., 2013; Fenster et al., 2013).  It has been previously established 
that the number of microbubbles viewed in the left heart is proportional to the amount 
of blood flow between the right and left atria (Fenster et al., 2013). Therefore, 
microbubbles that appeared in the left heart were counted in order to classify the size of 
the PFO. After the release of a Valsalva maneuver, subjects that showed ≤ 12 
microbubbles in the left heart within 3 cardiac cycles were classified as having a small 
PFO (PFO+), while subjects with ≥ 13 bubbles visualized in the left heart were 
determined to have a large PFO (PFO+), as before (Davis et al., 2015, Norris et al., 
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2015). If no microbubbles appeared in the left heart within 20 cardiac cycles of saline-
contrast injection, the absence of both a PFO (PFO-), as well as blood flow through 
intrapulmonary shunts, was confirmed.  
 
Pulmonary Function Testing 
Pulmonary function testing (PFT) was performed to ensure that all subjects 
exhibited normal pulmonary function and did not demonstrate signs of lung disease. 
Baseline PFT measures were obtained using a computerized spirometry system (Ultima 
PFX, Medgraphics, St Paul, MN, USA) according to standards established by the 
American Thoracic Society/European Respiratory Society (ATS/ERS) (Macintyre et al., 
2005). Measures obtained for this experiment included forced vital capacity (FVC), 
volume of air forcefully expired in one second (FEV1), mid-expiratory flow rate 
(FEV25-75) and slow vital capacity (SVC). Whole-body plethysmography was utilized to 
determine lung volume measurements, including total lung capacity (TLC), residual 
volume (RV) and functional residual capacity (FRC) (Wanger et al., 2005). Lung 
diffusion capacity for carbon monoxide (DLCO) was measured using a MedGraphics 
Elite Series Plethysmograph (MedGraphics Ultima PFX, Breeze v.6.3.006) and the 
single breath, breath-hold technique (Knudson et al., 1987; Macintyre et al., 2005). All 
subjects included in this study demonstrated FVC, FEV1, and FVC/FEV1 values ≥ 85% 
of predicted values determined by height and weight, indicating normal lung function.  
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End-Tidal Forcing System 
A dynamic end-tidal forcing system (DEF) designed by Foster et al. (Querido et 
al., 2013; Bain et al., 2013; Foster et al., 2014) was utilized to control and estimate 
arterial blood gases. The DEF method relies on real-time feedback information to 
regulate and maintain the end-tidal partial pressure of O2 (PETO2) and the end-tidal 
partial pressure of CO2 (PETCO2) by analyzing expired air and adjusting fractions of 
inspired O2 (FiO2) and CO2 (FiCO2) on a breath-by-breath basis (Tymko et al., 2015). 
Specific to this experiment, the end-tidal forcing system was employed to measure and 
quantify responses of the central and peripheral chemoreceptors to normoxic and 
hyperoxic hypercapnia conditions.  
 Throughout the study, all respiratory parameters were measured at 200 Hz using 
a personal computer and the DEF system interfaced with an analog-to-digital converter 
(Powerlab/16SP ML 880; ADInstruments, Colorado Springs, CO). Respiratory and 
cardiovascular data were analyzed using commercially available software (LabChart 
V7.1, ADInstruments, Colorado Springs, CO, USA).  All trials required that subjects 
were instrumented with a nose clip and breathed through a mouthpiece with a biological 
filter and two-way nonrebreathing valve (7900 series, Hans Rudolph, Shawnee, KS). 
Prior to each trial, a pneumotachograph (HR 800L, Hans Rudolph) and differential 
pressure amplifier (ML 141, ADInstruments), utilized to measure respiratory flow, were 
calibrated with a 3-liter syringe.  
 End-tidal partial pressures of O2 and CO2 were maintained using the portable 
DEF system. Each trial required that varying proportions of N2, CO2 and O2 were 
delivered to the subject for inhalation in order to regulate PETO2 and PETCO2 as 
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previously described (Foster et al., 2014). The DEF system utilizes independent 
solenoid valves to deliver N2, CO2 and O2, which are then combined and sent through a 
humidification chamber before delivery to the subject through the pneumotach’s 
inspiratory port. PETCO2, PETO2, tidal volume (VT), breathing frequency (F) and 
minute ventilation (VE) are determined for each exhalation using specifically designed 
software (Labview 13.0, National Instruments, Austin, TX). The DEF system then 
utilizes this feedback information to determine the composition of inspired air needed to 
adjust PETO2 and PETCO2 to target values.  
 
Study Protocol 
Following PFO screening and pulmonary function testing, subjects returned to 
the Cardiopulmonary and Respiratory Physiology Lab in the Center for Medical 
Education and Research for one day to complete the study day protocol. After subject 
arrival, researchers obtained height and weight using a stadiometer and electronic scale 
(Ohaus Corporation, ES200L, Pinebrook, NJ, USA), respectively. In addition, female 
subjects were tested to rule out pregnancy as an exclusion criteria; no females were 
found to be pregnant. Each subject was then seated in an upright IV chair and 
instrumented with necessary devices for a wide range of data collection. A finger pulse 
oximeter (ADInstruments, Colorado Springs, CO, USA) was utilized to monitor oxygen 
saturation. The subject was instrumented with a 3-lead ECG on the right and left 
collarbone and right hip areas for continuous heart rate acquisition. In addition, the 
subject was outfitted with a standard blood pressure cuff for instantaneous blood 
pressure measures.  
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Each subject underwent two hypercapnic breathing trials in a randomized and 
balanced order. For each trial, the subject began breathing room air on a two-way 
nonrebreathing mouthpiece (model 2400, Hans Rudolph, Kansas City, MOS) and 
pneumotachograph (HR 800L, Hans Rudolph) with nose clip. The subject continued to 
breathe room air until PETO2 and PETCO2 values stabilized, at which “steady state” was 
achieved. Two breathing trials were then implemented with a 40-minute resting period 
between trials. - Hyperoxic Hypercapnia: Subjects began breathing room air on the 
mouthpiece to establish baseline steady state values for PETO2 and PETCO2. 
Once baseline was established, end-tidal O2 was clamped at 250 mmHg 
(hyperoxia) while resting PETCO2 was maintained. Steady state was 
achieved when end-tidal values remained within 1 mmHg of desired values 
for three consecutive breaths and subjects then remained at steady state for 
five minutes. The fraction of inspired carbon dioxide (FiCO2) was then 
adjusted to increase PETCO2 to the baseline resting measure +3 mmHg. 
After reaching steady state, subjects remained at this stage for 90 seconds 
before moving to the next stage. This procedure was then repeated for 
PETCO2 values of +6 and +9 mmHg above the established resting baseline 
value.  - Normoxic Hypercapnia: Subjects began breathing room air on the 
mouthpiece to establish baseline steady state values for PETO2 and PETCO2. 
Once baseline was established, end-tidal O2 and CO2 were clamped at 
resting values. Steady state was achieved when end-tidal values remained 
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within 1 mmHg of desired values for three consecutive breaths and subjects 
then remained at steady state for five minutes. FiCO2 was then adjusted to 
increase PETCO2 to the baseline resting measure +3 mmHg. After reaching 
steady state, subjects remained at this stage for 90 seconds before moving to 
the next stage. This procedure was then repeated for PETCO2 values of +6 
and +9 mmHg above resting value.  
Statistical Analysis 
 GraphPad Prism software (v 7.0b) was used for data analysis. Anthropometric 
data was analyzed using unpaired t-tests. Overall and group descriptive statistics (mean 
and standard deviation) were calculated for all test variables. To determine differences 
in ventilatory responses between groups, HCVR was calculated as the slope of the VE 
versus PETCO2 regression line for each subject in each trial. Group HCVR values were 
calculated as the average of the slopes of each individual subject. Group averages were 
compared and analyzed using unpaired t-tests with an α-level of .05. All other 
cardiovascular variables were compared using a two-way repeated measures ANOVA. 
One PFO+ subject was excluded from the hyperoxic hypercapnia trial after data 
analysis determined that the subject’s HCVR was greater than two standard deviations 
above the group mean, fulfilling qualifications for a statistical outlier.    
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Results 
 
Anthropometrics and Lung Function 
There were no significant differences between groups in anthropometric, pulmonary 
function, or DLCO measures (p > .05) (Table 1). 
 
Cardiorespiratory Measures 
There was no effect of PFO on VE, VT, RR, PETO2 or PETCO2 during the normoxic 
hypercapnia (NH) or hyperoxic hypercapnia (HH) trials (p > .05) (Table 2).  
 
Hypercapnic Ventilatory Response 
All subjects demonstrated a hypercapnic ventilatory response and significantly 
increased ventilation in response to acute normoxic (Figure 3A) and hyperoxic (Figure 
3B) hypercapnia, as expected. There was a main effect of PFO on HCVR during acute 
exposure to normoxic hypercapnia and hyperoxic hypercapnia. During the NH trial 
PFO+ subjects exhibited a significantly lower HCVR when compared to PFO- subjects 
(p < .05) (Figure 4A). Additionally, PFO+ subjects demonstrated a blunted HCVR in 
the HH trial compared to PFO- subjects (p > .05) (Figure 5A).  
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Effect of Biological Sex 
There was no effect of biological sex on HCVR in the HH and NH trials. When 
examining individual sexes, there were no significant differences between PFO+ 
subjects and same sex PFO- subjects, likely driven by relatively low subject numbers. 
In the NH trial, the female PFO+ subjects trended toward a blunted HCVR when 
compared to female PFO- subjects (Figure 4B, p = .06). In addition, there were no 
significant differences between the male PFO+ and PFO- subjects, though the data 
trended in the direction of differences seen in all subjects (Figure 4C, p = .17). 
Similarly, in the HH trial female PFO+ subjects trended toward a blunted HCVR when 
compared to female PFO- subjects (Figure 5B, p = .06). Similar to the NH trial, there 
were no significant differences between the male PFO+ and PFO- subjects in the HH 
trial, though the data trended in the direction of differences seen in all subjects (Figure 
5C, p = .15). Furthermore, there was no effect of biological sex on HCVR within the 
PFO+ and PFO- groups (p > .05, data not shown).  
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Discussion 
The purpose of this study was to determine the effect of a patent foramen ovale 
(PFO) on the hypercapnic ventilatory response (HCVR). It was hypothesized that 
subjects with a PFO (PFO+) would exhibit a blunted HCVR in response to acute 
hyperoxic hypercapnia (HH) as well as acute normoxic hypercapnia (NH) when 
compared to subjects without a PFO (PFO-).  
 
The Hypercapnic Ventilatory Response 
 The human hypercapnic ventilatory response (HCVR) is a well-established and 
extensively researched phenomenon. Unsurprisingly, all subjects included in this study 
demonstrated an increase in resting minute ventilation (VE) in response to normoxic 
hypercapnic (Figure 3A) and hyperoxic hypercapnic (Figure 3B) experimental 
conditions. The results of this experiment support previous findings, which demonstrate 
changes in ventilation in response to corresponding changes in PaCO2 in both normoxic 
and hyperoxic hypercapnic conditions in healthy, non-smoking subjects (Duffin, 2007). 
Thus, we were able to successfully increase PETCO2 in a step-wise fashion and elicit an 
increase in VE, as expected. Although all subjects when grouped together exhibited an 
anticipated HCVR, separating subjects based on the presence or absence of a PFO 
revealed differing responses between groups.  
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Effect of a PFO on the Hypercapnic Ventilatory Response  
 Individuals with a PFO have previously demonstrated blunted ventilatory 
responses to chronic hypoxia (Elliott et al., 2015) as well as acute thermoregulatory 
challenges (Davis et al., in review). Similarly, the results of this experiment indicate a 
difference in ventilatory responses between PFO+ and PFO- subjects. PFO+ subjects 
demonstrated a blunted, significantly lower HCVR to normoxic hypercapnic (Figure 
4A) as well as hyperoxic hypercapnic (Figure 5A) conditions compared to PFO- 
subjects. These data suggest that the presence of a PFO is correlated with decreased 
chemoreceptor sensitivity to increased CO2. PFO+ subjects exhibited a diminished 
ventilatory response to increased PETCO2 compared to PFO- subjects in the NH and HH 
trials, despite the fact that PETCO2 values were similar between groups (Table 3). As 
speculated by Elliott et al. regarding differences in HVR between PFO+ and PFO- 
subjects after 16 days at altitude, it is possible that the blunted HCVR in PFO+ subjects 
may hint at an appropriate, advantageous response in individuals with right-to-left 
intracardiac shunting (2015). Increasing ventilation in response to hypoxic or 
hypercapnic challenges increases metabolic demand due to increased recruitment, and 
therefore energy demand and waste production, of muscles required for respiration. 
Right-to-left shunting in PFO+ subjects impairs their ability to increase PaO2 and 
decrease PaCO2. Therefore, it is possible that the increased waste production and 
metabolic demand associated with increasing ventilation would negate the benefits of 
increasing ventilation to decrease PaCO2 in PFO+ subjects, leading to decreased HCVR 
compared to PFO- subjects.  
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The results of both the NH and HH trials, when evaluated together, suggest that 
there is a central chemoreceptor component to the differences in ventilatory responses 
between PFO+ and PFO- subjects to acute hypercapnia, but a negligible peripheral 
chemoreceptor component. PFO+ subjects had a  ~0.5 L/min/mmHg CO2 lower average 
HCVR in both the NH and HH trial compared to PFO- subjects, indicating that 
dampening the output of the peripheral chemoreceptors in the HH trial had no impact on 
the difference between PFO+ and PFO- HCVR and that the difference in responses 
between groups are likely centrally driven (Figure 6). These results support the findings 
of an accompanying study conducted by the Cardiopulmonary and Respiratory 
Physiology Lab, which demonstrates no differences in ventilation between PFO+ and 
PFO- subjects in response to acute exposure to isocapnic and poikilocapnic hypoxia 
(unpublished data). In addition, these data are supported by previous research that 
indicates that there are no significant differences between PFO+ and PFO- subjects in 
the hypoxic ventilatory response (HVR) after one day of exposure to hypoxia at high 
altitude (Elliott et al., 2015). The results of all three studies, taken in combination, 
suggest that there is no effect of PFO on peripheral chemoreceptor sensitivity, and 
therefore no differences in ventilatory responses as a result of peripheral chemoreceptor 
activity, during acute exposure to hypoxia or hypercapnia.  
 
Effect of Biological Sex and PFO on the Hypercapnic Ventilatory Response  
 Female PFO+ subjects trended toward a lower HCVR than female PFO- 
subjects in both the HH (Figure 4B) and NH (Figure 5B) trials. Similarly, male PFO+ 
subjects trended toward a lower HCVR than male PFO- subjects in both the HH (Figure 
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4C) and NH (Figure 5C) trials. Thus, there was no influence of biological sex on the 
effect of PFO on HCVR. These results denote that without controlling for menstrual 
cycle phase, PFO+ subjects exhibit a lower HCVR than PFO- subjects, suggesting that 
the differences observed between groups were driven by PFO, rather than biological 
sex. In addition, there was no effect of biological sex on HCVR within the PFO- and 
PFO+ groups (p > .05, data not shown).  The results of the present study are consistent 
with and confirm the findings of MacNutt et al., validating that even without controlling 
for the presence of a PFO, there was no effect of biological sex on HCVR (2012).  
 
Clinical Relevance and Significance 
Ventilatory control and chemoresponsiveness have previously been identified as 
important factors in obstructive sleep apnea (OSA) pathogenesis, as hypoventilation and 
obstructive events occur during stages of low respiratory drive (Dempsey et al., 2005; 
Eckert et al., 2008). Therefore, a relatively greater hypoventilation during sleep in 
individuals with PFO may represent an important potential contributing factor to OSA 
susceptibility and severity. As described before, multiple studies have established an 
increased prevalence of PFO among individuals with OSA (Shanoudy et al., 1998; 
Guchlerner et al., 2012; Shaikh et al., 2013). However, the physiological mechanisms 
underlying this correlation were previously undetermined. The results of this study 
represent novel findings that may provide meaningful insight into the connection 
between OSA and PFO and contribute to clinical understanding of this life-threatening 
sleep pathology.  
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The present study determined that PFO+ subjects have a significantly lower 
HCVR than PFO- subjects. Thus, PFO+ subjects are prone to hypoventilate at increased 
PaCO2 levels. A comprehensive review into the pathophysiology of sleep apnea 
determined that both hyperventilation and hypoventilation in conditions of fixed, resting 
CO2 production destabilize the respiratory control system and increase susceptibility for 
apnea. By this model, hypoventilation, which results in higher resting PACO2, places an 
individual at a greater risk of apnea, as a smaller increase in ventilation is required to 
overshoot the apneic threshold and result in a cessation of breathing (Figure 2A, 
Dempsey, 2005). A decreased HCVR, and therefore slope of the ∆VE - ∆PACO2 
relationship, appears to decrease susceptibility to apnea (Figure 2B, Dempsey, 2005).  
However, overlaying these two figures and combining decreased HCVR with 
hypoventilation, which may be representative of some PFO+ individuals, leads to a 
similar increase in susceptibility of crossing the apneic threshold and developing a 
periodic breathing pattern during sleep.  
As previously described, the decreased HCVR observed in PFO+ subjects in this 
study signifies decreased chemoreceptor sensitivity to increased PaCO2. An important 
aspect of obstructive sleep apnea pathophysiology is a loss of muscle tone to the 
genioglossus, or tongue, muscle that occurs during NREM and REM sleep, resulting in 
partial or full blockage of the upper airway. Horner et al. utilized a rodent model to 
demonstrate decreased chemoreceptor stimulation to the genioglossus muscle despite 
significant increases CO2 during NREM and REM sleep compared to a wakeful state. 
This study concluded that chemoreceptor stimulation to the genioglossus muscle is 
blunted during sleep and greater increases in PaCO2 are required to elicit a response 
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from the genioglossus muscle during NREM sleep compared to wakefulness. Further, 
no degree of increased PaCO2 was sufficient to increase genioglossus tone during REM 
sleep. Decreased genioglossus muscle tone during sleep is an important contributing 
factor to the loss of upper airway patency observed in OSA. Therefore, the decreased 
chemoresponsiveness to increased PaCO2 observed in PFO+ subjects in the present 
study may indicate that these subjects also have decreased chemoreceptor stimulation to 
the genioglossus muscle, increasing the probability of obstruction and upper airway 
closure. However, this remains speculative. 
In addition to potentially increasing the probability of obstruction, the presence 
of a PFO may influence the severity of the effects of obstruction when it does occur. A 
study conducted by Johansson et al. determined that oxygen desaturation occurs more 
often in proportion to the number of blockages in PFO+ subjects than in subjects 
without a PFO. The study concluded that there was a significantly higher prevalence 
(60%) of large PFO among subjects with a high proportional desaturation (PD) value, as 
measured by the oxygen desaturation index (ODI)/ apnea-hypopnea index (AHI) ratio, 
than among subjects with a low PD value (13%). Thus, subjects with a large PFO 
experienced a greater degree of hypoxemia per apnea (Johansson et al., 2007). In 
addition, Beelke et al. found that right-to-left shunting occurred in 9 out of 10 PFO+ 
subjects during an obstructive apnea lasting longer than 17 seconds (2003). Taken in 
combination with the results of the present study, these conclusions may provide insight 
into the decreased severity of sleep apnea observed after PFO closure (Rimoldi et al., 
2015). The present study determined that PFO+ subjects have a decreased HCVR 
compared to PFO- subjects. Therefore, it is possible that a greater increase in PaCO2 as 
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a result of apnea is necessary to elicit a response significant enough to arouse an 
individual with a PFO, potentially leading to longer apneas in PFO+ subjects. If this 
were true, the conclusions of Beelke et al. would suggest that longer apneas in PFO+ 
subjects would also lead to right-to-left shunting (RTLS), increasing the degree of 
hypoxemia as a result of the apnea. This proposed pathway aligns with the findings of 
Johansson et al.; longer apneas as a result of decreased HCVR, leading to increased 
RTLS and a greater degree of hypoxemia, could explain the greater proportional oxygen 
desaturation observed in subjects with large PFO. Thus, PFO and a corresponding 
decreased HCVR may lead to a greater severity of the effects of obstruction, worsening 
OSA severity. However, additional research is required to confirm the proposed 
mechanisms outlined whereby a PFO may contribute to central and obstructive sleep 
apnea (Figure 7). 
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Conclusion 
 While previous research has determined several effects of a PFO on normal 
physiology, it was undetermined if the presence of a PFO influences ventilatory 
responses to acute hypercapnic challenges. The high prevalence of PFO in the general, 
healthy population (25-40%) and even higher prevalence in some disease populations 
(43-72%) validates the importance of research into how this right-to-left shunt pathway 
may affect various physiological processes. The results of this study indicate that PFO+ 
individuals have a blunted ventilatory response to both normoxic and hyperoxic 
hypercapnia compared to PFO- individuals, suggesting that the presence of a PFO 
influences central chemosensitivity to increased PETCO2. These findings may provide 
insight into the increased prevalence of PFO in sleep apnea patients and contribute to 
understanding of the pathogenesis of both central and obstructive sleep apnea.  
  
 
 
 
 
 
 
 
 
 
   30 
Limitations 
This experiment did not measure and control for menstrual cycle phase of 
female subjects. Consequently, it was assumed that the sample of females included in 
the study represents a range of sex hormone levels and varied stages of the menstrual 
cycle. Thus, although unlikely, it is possible that a disproportionate number of subjects 
participated in the experiment during any specific phase of the menstrual cycle, 
potentially skewing data and contributing to, or retracting from, the results observed. 
However, previous research demonstrates no effect of menstrual cycle phase on HCVR 
or HVR (MacNutt et al., 2012). Therefore, potential effects of menstrual cycle on the 
observed results are improbable and likely negligible.  
In addition, this study utilized end-tidal gases using a dynamic end-tidal forcing 
system (DEF) as an estimation of arterial blood gases. DEF induced hypercapnia is 
known to increase PETCO2 relative to PaCO2 as a proportion of inspired CO2 occupies 
dead space and mixes with expired air, leading to inflated PETCO2 values. However, the 
end-tidal-to-arterial PCO2 gradient is typically insignificant at rest (Tymko et al., 2016). 
All breathing trials were performed in resting conditions, indicating that end-tidal gases 
likely served as an accurate estimation of arterial blood gases and only minimally 
contributed to experimental error.  
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Figures 
 
 
Figure 1: Cardiopulmonary circulation. 
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Figure 2: The pathway of blood flow through a patent foramen ovale (PFO). 
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Tables 
 
 
 
 
PFO+ 
 
PFO- 
 
All 
 
Male           
n = 7 
Female           
n = 8 
Overall           
n = 15 
 
Male 
n = 7 
Female 
n = 9 
Overall 
n = 16 
 
Male 
n = 14 
Female 
n = 17 
Overall 
n = 31 
Age (y) 28 ± 6 21 ± 1 24 ± 5 
 
28 ± 9 25 ± 10 27 ± 9 
 
28 ± 7 23 ± 7 25 ± 7 
Height 
(cm) 180 ± 9 163 ± 8 171 ± 12 
 
180 ± 6 165 ± 6 172 ± 10 
 
180 ± 7 164 ± 7 171 ± 11 
Weight 
(kg) 82 ± 10 59 ± 8 69 ± 14 
 
82 ± 15 59 ± 5 71 ± 16 
 
82 ± 12 59 ± 6 70 ± 15 
BSA (m2) 2.0 ± 0.2 1.6 ± 0.1 1.8 ± 0.2 
 
2.0 ± 0.2 1.6 ± 0.1 1.8 ± 0.2 
 
2.0 ± 0.2 1.6 ± 0.1 1.8 ± 0.2 
FVC (L) 5.6 ± 1.1 3.7 ± 0.4 4.5 ± 1.2 
 
5.4 ± 0.5 3.9 ± 0.6 4.6 ± 0.9 
 
5.5 ± 0.8 3.8 ± 0.5 4.6 ± 1.1 
FEV1 (L)  4.5 ± 0.9 3.1 ± 0.4 3.9 ± 1.0 
 
4.3 ± 0.5 3.2 ± 0.5 4.0 ± 0.7 
 
4.4 ± 0.7 3.1 ± 0.5 3.7 ± 0.9 
DLCO 
(ml/ 
min/Torr) 
45 ± 8 28 ± 6 38 ± 10  40 ± 6 32 ± 4 36 ± 7  42 ± 7 30 ± 5 37 ± 8 
 
Table 1: Anthropometric and pulmonary function testing data. All values are means ± 
standard deviations. No significant differences between groups (p > .05). 
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Table 2: Ventilatory and metabolic measures. Values are means ± standard deviation. 
No significant differences between groups (p > .05). 
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 All  Female  Male 
PFO+ 
n = 15 
PFO- 
n = 16  
PFO+ 
n = 8 
PFO- 
n = 9  
PFO+ 
n = 7 
PFO- 
n = 7 
NH 1.4 ± 0.5*  2.0 ± 0.8  1.4 ± 0.5 1.9 ± 0.6  1.4 ± 0.5 2.0 ± 1.0 
HH 1.3 ± 0.6* 1.8 ± 0.7  1.2 ± 0.4 1.7 ± 0.6  1.2 ± 0.8 1.8 ± 0.9 
 
Table 3: Average HCVR slopes for all conditions and all groups. Values are means ± 
standard deviation. * indicates significant difference between PFO+ and PFO- groups 
(p < .05).   
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Figure 3A: The hypercapnic ventilatory response to acute normoxic hypercapnia for all subjects. Points 
and bars on figure are mean ± standard error. * indicates significant difference in PETCO2 from resting 
baseline (p < .05).  § indicates significant difference in VE from resting baseline (p < .05). 
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Figure 3B: The hypercapnic ventilatory response to acute hyperoxic hypercapnia for all subjects. Points 
and bars on figure are mean ± standard error. * indicates significant difference in PETCO2 from resting 
baseline (p < .05).    § indicates significant difference in VE from resting baseline (p < .05).  
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Figure 4A: The effect of a PFO on HCVR during acute exposure to normoxic hypercapnia for all 
subjects. Bold dashed line represents average HCVR for PFO+ subjects and bold solid line represents 
average HCVR for PFO- subjects. There was a main effect of PFO on HCVR. * indicates a significant 
difference in slope from PFO+ subjects (p < .05).  
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Figure 4B: The effect of a PFO on HCVR during acute exposure to normoxic hypercapnia for female 
subjects. Bold dashed line represents average HCVR for PFO+ subjects and bold solid line represents 
average HCVR for PFO- subjects. No significant differences between groups (p > .05). 
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Figure 4C: The effect of a PFO on HCVR during acute exposure to normoxic hypercapnia for male 
subjects. Bold dashed line represents average HCVR for PFO+ subjects and bold solid line represents 
average HCVR for PFO- subjects. No significant differences between groups (p > .05). 
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Figure 5A: The effect of a PFO on HCVR during acute exposure to hyperoxic hypercapnia for all 
subjects. Bold dashed line represents average HCVR for PFO+ subjects and bold solid line represents 
average HCVR for PFO- subjects. There was a main effect of PFO on HCVR. * indicates a significant 
difference in slope from PFO+ subjects (p < .05).  
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Figure 5B: The effect of a PFO on HCVR during acute exposure to hyperoxic hypercapnia for female 
subjects. Bold dashed line represents average HCVR for PFO+ subjects and bold solid line represents 
average HCVR for PFO- subjects. No significant differences between groups (p > .05).  
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Figure 5C: The effect of a PFO on HCVR during acute exposure to hyperoxic hypercapnia for male 
subjects. Bold dashed line represents average HCVR for PFO+ subjects and bold solid line represents 
average HCVR for PFO- subjects. No significant differences between groups (p > .05).  
 
 
 
 
 
 
 
 
  44 
 
 
Figure 6: Comparison of average HCVR slopes for PFO+ and PFO- subjects between normoxic 
hypercapnia and hyperoxic hypercapnia trials. There was a main effect of PFO on HCVR slope during the 
normoxic hypercapnia and hyperoxic hypercapnia trials. Values are means ± standard deviation. * 
indicates a significant difference in slope between PFO+ and PFO- subjects (p <.05). 
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Figure 7: Flow chart demonstrating proposed correlations between PFO and OSA. 
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